Brookfield Corp’s Travere Therapeutics TVTX Stock Holding History

Brookfield Corp’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-47,854	Closed	-$1.16M	–	773
2022 Q2	$1.16M	Buy	+47,854	New	+$1.2M	﹤0.01%	485

Other funds holding TVTX

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Brookfield Corp's TVTX Position: Q3 2022 in Review

Brookfield Corp sold out of Travere Therapeutics (TVTX) in Q3 2022, closing a stake of 47,854 shares — an estimated $1.16M sold.

Brookfield Corp first reported a position in TVTX in Q2 2022 and held it in 1 quarter. The position peaked at $1.16M in Q2 2022. 171 funds tracked by Wall St. Rank hold TVTX as of Q3 2022.

Brookfield Corp reported no remaining Travere Therapeutics position as of Q3 2022 after selling out during the quarter.
Brookfield Corp sold 47,854 Travere Therapeutics shares in Q3 2022, an estimated $1.16M.
Brookfield Corp first reported a position in Travere Therapeutics in Q2 2022 and held it in 1 quarter.
Brookfield Corp's Travere Therapeutics position peaked at $1.16M in Q2 2022.
171 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2022.

Based on Brookfield Corp's 13F filing for Q3 2022, filed 14 Nov 2022.